Balanced news tone
News Sentiment
NTI sentiment intelligence
Neurotech International Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
93/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +30.8% over four weeks, trend inactive, and below fair value.
Neurotech International (ASX:NTI) Rises 12.5% — What Is Driving the Paediatric Health Technology Stock?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Neurotech International (ASX:NTI) Rises 12.5% — What Is Driving the Paediatric Health Technology Stock?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 05:11
- Source
- Kalkine
Neurotech International (ASX:NTI) Gets FDA Green Light to Start US Trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:42
- Source
- Kalkine
Neurotech International Ltd (ASX: NTI) Shares Rally as Investors Monitor Clinical Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 02:48
- Source
- Kalkine
Health Check: Neurotech shares soar 30% on US cannabis trial breakthrough
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 02:47
- Source
- Stockhead
Neurotech International issues 19.5M unlisted options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 00:36
- Source
- grafa.com
Neurotech (ASX:NTI) clears FDA IND for NTI164 and the partnering conversation just got real
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 00:35
- Source
- Stocks Down Under
Neurotech International Announces Proposed Issue of Securities to Enhance Capital Structure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:40
- Source
- Kalkine
Neurotech (ASX:NTI) Strengthens NTI164 Position with US Patent Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 01:51
- Source
- Kalkine
Inside Biotech: Neurotech moves from research labs to real-world healthcare
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Proactive financial news
‘Doesn’t align’: Neurotech star slams start-up tax
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- The Australian
Neurotech opens first phase III trial site
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- The Australian
Neurotech International (ASX: NTI) Gains 10%: Can This Biotech Micro-Cap Deliver a Breakthrough in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Kalkine
Why Neurotech International (ASX:NTI) Stock Is Moving Today: Phase 3 Autism Trial Begins at Major Hospital
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- Kalkine
Neurotech’s NTI164 shows strong long-term safety
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Feb 2026 08:00
- Source
- The Australian
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 01 Feb 2026 08:00
- Source
- smallcaps.com.au
NRFC invests $20m in AI neurotech firm Omniscient
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jan 2026 08:00
- Source
- Information Age | ACS
Neurotech raising $4 million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Dec 2025 08:00
- Source
- The Australian
Neurotech gains FDA rare disease nod for NTI164
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Oct 2025 07:00
- Source
- The Australian